title: Expression of MACC1 and MET in inflammatory bowel disease-associated colonic neoplasia.
abstract: BACKGROUND
  Metastasis-associated in colon cancer-1 (MACC1), a newly identified regulator of HGF-MET signaling, may participate into the key steps of sporadic colorectal adenocarcinoma development. Given there are many pathogenetic distinctions between colitis-associated colorectal cancer (CAC) and sporadic colorectal adenocarcinomas, the potential roles of MACC1 in CAC carcinogenesis remain unknown. For the first time, we evaluated the expressions of MACC1 and MET in IBD-associated colitis, dysplasia, and adenocarcinoma.
  
  
  METHODS
  Expression was investigated by immunohistochemistry in tissue microarrays consisting of 13 normal colon, 11 active colitis, 9 dysplasia, 51 conventional CAC, 5 mucinous adenocarcinoma, and 1 signet ring cell adenocarcinoma specimens. The expression level of MACC1 or MET was evaluated with H-score system.
  
  
  RESULTS
  MACC1 expression was significantly higher in IBD-associated dysplasia than that in corresponding inflammatory or normal colonic tissue, and its level was further elevated from dysplasia to conventional CAC. Higher MACC1 expression was seen in a patient with CAC who had multifocal dysplasia or synchronous carcinoma. MACC1 overexpression (H-score >100) was seen in 67% of conventional CAC but in 0% of dysplasia and 0% of inflammation or normal colon. There was no difference of MACC1 expression found among well, moderately and poorly differentiated CAC. MET expressions in inflammation, dysplasia, and conventional CAC were statistically similar. No parallel expression of MACC1 and MET was detected in this study. MACC1 and MET expression was not increased in mucinous or signet ring cell carcinoma, 2 distinct variants of CAC.
  
  
  CONCLUSIONS
  Stepwise increase of MACC1 expression from IBD-associated colitis to dysplasia to adenocarcinoma suggests that MACC1 is strongly associated with conventional CAC tumorigenesis in a manner independent of MET. MACC1 may serve as a potential marker for early diagnosis of conventional CAC.
authors: *Department of Pathology, Mount Sinai Medical Center, New York, New York; †Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York; and ‡Department of Pathology and Laboratory Medicine, UCLA Center for the Health Science, Los Angeles, California.
authors: Noam
authors: N
authors: Harpaz
authors: Sofia
authors: S
authors: Taboada
authors: Huaibin Mabel
authors: HM
authors: Ko
authors: Jiangzhou
authors: J
authors: Yu
authors: Qi
authors: Q
authors: Yang
authors: Haodong
authors: H
authors: Xu
authors: Wenqing
authors: W
authors: Cao
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000737:chemistry; D000328:Adult; D000368:Aged; D018279:Carcinoma, Signet Ring Cell / Q000737:chemistry; D003093:Colitis, Ulcerative / Q000378:metabolism* / Q000473:pathology; D003106:Colon / Q000737:chemistry; D015179:Colorectal Neoplasms / Q000737:chemistry* / Q000473:pathology; D003424:Crohn Disease / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D019859:Proto-Oncogene Proteins c-met / Q000032:analysis* / Q000378:metabolism; D015534:Trans-Activators; D014157:Transcription Factors / Q000032:analysis* / Q000378:metabolism; D055815:Young Adult
chemical_list: C544162:MACC1 protein, human; D015534:Trans-Activators; D014157:Transcription Factors; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met